General Information
Drug ID
DR01383
Drug Name
Camptothecin
Synonyms
camptothecin; Camptothecine; 7689-03-4; (S)-(+)-Camptothecin; Campathecin; d-Camptothecin; (+)-Camptothecine; (+)-Camptothecin; 20(S)-Camptothecine; 21,22-Secocamptothecin-21-oic acid lactone; NSC94600; (S)-Camptothecin; Camptothecine (8CI); 20(S)-Camptothecin; Camptothecine (S,+); CHEMBL65; UNII-XT3Z54Z28A; MLS000766223; (4S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; XT3Z54Z28A; CHEBI:27656; VSJKWCGYPAHWDS-FQEVSTJZSA-N; Camptothecin, Camptotheca acuminata; NSC-94600; Camptothecin derivat
Drug Type
Small molecular drug
Indication Non-small cell lung cancer [ICD11: 2C25] Phase 3 [1]
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=24360"></iframe>
3D MOL 2D MOL
Formula
C20H16N2O4
Canonical SMILES
CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O
InChI
InChI=1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3/t20-/m0/s1
InChIKey
VSJKWCGYPAHWDS-FQEVSTJZSA-N
CAS Number
CAS 2086-83-1
Pharmaceutical Properties Molecular Weight 348.4 Topological Polar Surface Area 79.7
Heavy Atom Count 26 Rotatable Bond Count 1
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 5
PubChem CID
24360
PubChem SID
5009 , 399733 , 597746 , 842008 , 925175 , 3140967 , 7887296 , 7978848 , 8139651 , 8150064 , 8167780 , 10321203 , 11111011 , 11112910 , 11113913 , 11120280 , 11120768 , 11121256 , 11336001 , 11341983 , 11361240 , 11362166 , 11363193 , 11365755 , 11368317 , 11372185 , 11374175 , 11376479 , 11377982 , 11446457 , 11462212 , 11466228 , 11467348 , 11484482 , 11485816 , 11487568 , 11488719 , 11491018 , 11492553 , 11494113 , 11537709 , 14827597 , 14900711 , 17404904 , 24278352 , 26612343 , 26680346 , 26732559 , 26747153 , 26747154
ChEBI ID
ChEBI:16118
TTD Drug ID
D09YDM
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [3]
MRP4 Transporter Info Multidrug resistance-associated protein 4 Substrate [4]
References
1 ClinicalTrials.gov (NCT00826644) Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient
2 The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res. 2010 Jan;24(1):146-9.
3 Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010 Feb;44(2):152-67.
4 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.